NOVARX: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of NOVARX’s website, https://novarx.co, FDA Establishment Identifier (FEI) 3044022416, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “NOVA RX” on the pictured label, suggesting NOVARX is the compounder of those drugs when in fact it is not.”

2. 2

   “2. The following claims concerning compounded semaglutide products appear on your website: “…access to the same active ingredient found in Ozempic.” Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

3. 3

   “3. Your website claims that the compounded drug products it offers are sourced from “FDA Approved Pharmacies.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

novarx.co — the domain FDA reviewed — returned HTTP 503 on 2026-08-09, serving a WordPress holding page reading "Maintenance Mode. We're working a few things. We'll be back in some hours." Separately, novarx.com, the domain in the letter's contact address info@novarx.com, returned HTTP 200 but resolved to an unrelated third-party site titled "Togel Singapore: Keluaran SGP" with no NOVARX content. Neither result is proof of closure — a holding page can precede a relaunch and a lapsed secondary domain can be re-registered by anyone — so this is recorded as unknown.

Two of these findings are small enough to be easy to miss and are worth naming anyway. The label read "NOVA RX" while the company is NOVARX, and FDA still treated it as a representation that NOVARX compounded the drug — so a space in the middle of a word does not create distance between a brand and a product it did not make. And the credential claim said "FDA Approved Pharmacies", not the "FDA-licensed" phrasing most of this market uses. Approved is the stronger word and the more wrong one: FDA does not approve or license compounding pharmacies at all, so the more confident version of the claim is no more true than the cautious one. The part that bears on a purchase is separate from all of that. When we checked, the site FDA reviewed was serving a maintenance page and the domain on the company's own contact address had become something else entirely. That is not evidence the business has closed, and we have not recorded it as such. It is a reason to confirm a seller is actually there before sending money — which is ordinary caution, and not something the warning letter itself says.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence NOVARX failed to respond.